Sam Fazeli

It has nothing to do with that.

And also, it's continued to add significant value.

So that would be great to see.

Mark, I want to thank you again.

I think we're definitely over the one hour mark.

And it's been a great opportunity to catch up with you and hear the story.

I hope that in a year or two, or even sooner, I mean, AI moves very fast.

We can get back together and talk about some progress that the company has made.

Wonderful.

Thank you very much for your time.

I look forward to seeing you soon.

Thank you.

Hello, everybody.

Welcome to another episode of Bloomberg Intelligence Vanguards of Healthcare podcast.

It is the last one of the year for me, but it is with somebody whom I've known for a long, long time.

And it's a real pleasure to get back together, even if it's virtual at the minute.

And these podcasters, you know, we speak with the leaders at the forefront of change in the healthcare industry and no one

is closer to those changes than VCs, and no one's closer to those changes than VCs like Antoine that I've known for years.

So my name is Sam Fazelli, and I'm a former biotech analyst at Bloomberg Intelligence, which is the in-house research arm of Bloomberg.

Now, I'm thrilled to welcome Antoine Papiernique, a managing partner at Sofinova Partners.